Rocket Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell RCKT and other ETFs, options, and stocks.

About RCKT

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. 

CEO
Gaurav D. Shah
CEOGaurav D. Shah
Employees
202
Employees202
Headquarters
Cranbury, New Jersey
HeadquartersCranbury, New Jersey
Founded
1999
Founded1999
Employees
202
Employees202

RCKT Key Statistics

Market cap
386.30M
Market cap386.30M
Price-Earnings ratio
-1.73
Price-Earnings ratio-1.73
Dividend yield
Dividend yield
Average volume
1.98M
Average volume1.98M
High today
$3.57
High today$3.57
Low today
$3.43
Low today$3.43
Open price
$3.46
Open price$3.46
Volume
426.63K
Volume426.63K
52 Week high
$8.26
52 Week high$8.26
52 Week low
$2.19
52 Week low$2.19

Stock Snapshot

The current Rocket Pharmaceuticals(RCKT) stock price is $3.54, with a market capitalization of 386.3M. The stock trades at a price-to-earnings (P/E) ratio of -1.73.

On 2026-05-01, Rocket Pharmaceuticals(RCKT) stock moved within a range of $3.43 to $3.57. With shares now at $3.54, the stock is trading +3.2% above its intraday low and -0.7% below the session's peak.

Trading activity shows a volume of 426.63K, compared to an average daily volume of 1.98M.

Over the past 52 weeks, Rocket Pharmaceuticals(RCKT) stock has traded between a high of $8.26 and a low of $2.19.

Over the past 52 weeks, Rocket Pharmaceuticals(RCKT) stock has traded between a high of $8.26 and a low of $2.19.

RCKT News

TipRanks 3d
Rocket Pharmaceuticals Monetizes Voucher to Extend Cash Runway

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

TipRanks 3d
Rocket Pharmaceuticals announces $180M sale of priority review voucher

Rocket Pharmaceuticals (RCKT) announced a strengthened financial position following the sale of its Rare Pediatric Disease Priority Review Voucher, PRV. Rocket...

Analyst ratings

43%

of 14 ratings
Buy
42.9%
Hold
42.9%
Sell
14.3%

People also own

Based on the portfolios of people who own RCKT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.